Kelly Rauber
Personalreferent bei VERA THERAPEUTICS, INC.
Profil
Kelly Rauber is currently the Vice President & Head-Human Resources at Vera Therapeutics, Inc. Prior to this, Ms. Rauber held positions as the Senior Director-Human Resources at Dermira, Inc., Orchard Therapeutics Plc, and Oric Pharmaceuticals, Inc. Ms. Rauber completed their undergraduate degree at Santa Clara University.
Aktive Positionen von Kelly Rauber
| Unternehmen | Position | Beginn |
|---|---|---|
| VERA THERAPEUTICS, INC. | Personalreferent | 01.10.2022 |
Ehemalige bekannte Positionen von Kelly Rauber
| Unternehmen | Position | Ende |
|---|---|---|
| DERMIRA, INC. | Personalreferent | - |
| ORCHARD THERAPEUTICS PLC | Personalreferent | - |
| ORIC PHARMACEUTICALS, INC. | Personalreferent | - |
Ausbildung von Kelly Rauber
| Santa Clara University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ORIC PHARMACEUTICALS, INC. | Health Technology |
| VERA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Dermira, Inc.
 Dermira, Inc. Pharmaceuticals: MajorHealth Technology Dermira, Inc. is a biopharmaceutical company. It engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith on August 18, 2010 and is headquartered in Indianapolis, IN. | Health Technology |
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
